Print this page    •   Back to Web version of article

U.S. News
GlaxoSmithKline's Patent on Retrovir Expires; Generic Versions of AZT Expected to Be Available Soon

September 20, 2005

The patent on azidothymidine, or AZT -- the main ingredient in GlaxoSmithKline's antiretroviral drug Retrovir -- expired on Saturday, paving the way for lower-cost generic versions to be made available for millions of HIV-positive people in developing countries and thousands in the U.S., the Raleigh News & Observer reports (Vollmer [1], Raleigh News & Observer, 9/18). In the U.S., AZT currently is available only as Retrovir; however, drug companies in China, India and some African countries in July began preparing to make generic AZT. Generic versions could cost about $105 for an annual supply, roughly 20% less than the least expensive AZT currently available worldwide (Vollmer [2], Raleigh News & Observer, 9/18). When FDA first approved Retrovir in 1987, it cost up to $10,000 per person annually, but by 1989 the price was lowered to about $2,200 for an annual supply (Raleigh News & Observer [1], 9/18). GSK does not expect its revenue to be affected by the patent expiration because it will not affect the price of Combivir and Trizivir, its newest drugs containing AZT, which in 2004 brought in combined sales of $1.6 billion (Raleigh News & Observer [2], 9/18).

Back to other news for September 20, 2005

Reprinted with permission from You can view the entire Kaiser Daily HIV/AIDS Report, search the archives, or sign up for email delivery at The Kaiser Daily HIV/AIDS Report is published for, a free service of the Kaiser Family Foundation, by The Advisory Board Company. © 2005 by The Advisory Board Company and Kaiser Family Foundation. All rights reserved.

This article was provided by Henry J. Kaiser Family Foundation. It is a part of the publication Kaiser Daily HIV/AIDS Report. You can find this article online by typing this address into your Web browser:

General Disclaimer: is designed for educational purposes only and is not engaged in rendering medical advice or professional services. The information provided through should not be used for diagnosing or treating a health problem or a disease. It is not a substitute for professional care. If you have or suspect you may have a health problem, consult your health care provider.